Ardelyx Inc. recently announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its composition of matter patent application for RDX227675.
RDX227675 is Ardelyx’s proprietary oral, non-absorbed, potassium-binding polymer. When the patent is issued, RDX227675 will be given key intellectual property protection through the year 2035. Ardelyx also has multiple patent applications that will cover the composition and methods of RDX227675’s usage in the U.S. and internationally.
"When we originally conceived of the program we set a number of very specific goals for ourselves, such as eliminate sodium, optimize binding capacity, improve mouth feel, and develop formulations that would taste pleasant and be easier to ingest,” Mike Raab, President and CEO of Ardelyx, said. “We continue to believe that each of these characteristics is critical for the management of patients who have been prescribed beneficial medications such as ACE inhibitors and angiotensin II receptor blockers. This patent is a recognition that what we've accomplished is novel, and we expect RDX227675 will become be an important tool for physicians to help manage hyperkalemia.”
Hyperkalemia is a medical term for higher than normal levels of potassium levels in the blood. Hyperkalemia can show up in patients with chronic kidney disease or heart failure.
Ardelyx completed a $110 million private placement finance in July, advancing RDX227675 into a Phase III trial.
Alerts Sign-up